Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Theravance Faces Prospect Of Another Trial For Vibativ In Hospital-Acquired Pneumonia

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA says if it accepts pooling of mortality data from the drug's two nosocomial pneumonia studies, they would be considered a single trial.

You may also be interested in...



Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia

Theravance has received two complete response letters but says it does not plan to do additional clinical studies for the new indication; Vibativ production has been halted in the U.S. and its marketing authorization withdrawn in Europe.

FDA Found Answer To Vibativ Dilemma Of Teratogenicity Vs. Microbial Resistance In REMS

A Risk Evaluation and Mitigation Strategy that addresses the teratogenicity of Theravance’s Vibativ enabled FDA to manage an internal disagreement that pitted the drug’s risk to the unborn against the public health need for new antibiotics.

Advisory Committee Splits The Difference On CABP Trials

A fierce dispute between researchers and clinicians who think community-acquired bacterial pneumonia drugs should be evaluated by their effect on mortality, and those who favor symptom-based evaluation, is unlikely to be quelled by actions taken at the Dec. 9 meeting of FDA's Anti-Infective Drugs Advisory Committee, which gave each side some of what it wanted

Related Content

Topics

UsernamePublicRestriction

Register

PS070174

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel